United States Sickle Cell Disease (SCD) Treatment Market Outlook | New Drugs & High CAGR to Transform Healthcare 2025

DataM Intelligence has released an in-depth research report on "Sickle Cell Disease Treatment Market Size 2025". This report delivers power-packed insights into key growth drivers, market segmentation, regional trends, CAGR forecasts, revenue performance of top players, and emerging opportunities. Gain a 360° market perspective with detailed analysis on value, volume, and future development trends your ultimate guide to spotting high-impact opportunities and staying ahead in this dynamic market.

In December 2023, the U.S. FDA approved CASGEVY (exagamglogene autotemcel [exa-cel]), a CRISPR/Cas9-based gene editing therapy by Vertex Pharmaceuticals and CRISPR Therapeutics, for treating sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises. Vertex administered CASGEVY to the first patient in mid-2024.

On the same day, the FDA also approved bluebird bio's LYFGENIA (lovotibeglogene autotemcel) for the same indication, with bluebird targeting cell collections from 50 patients by March 31, 2025, and 70 by June 30, 2025.

Additionally, Enadri (L-glutamine oral powder) by Emmaus Medical continues to gain global approvals for sickle cell disease symptom management, including Bahrain (May 2023), Oman (July 2023), and Puerto Rico (February 2024).

Download Your Sample PDF Today and (Get Priority Access With a Corporate Email ID For Faster Delivery):- https://datamintelligence.com/download-sample/sickle-cell-disease-treatment-market?kb

Segment Drivers

Currently, two gene therapies Casgevy (Vertex & CRISPR Therapeutics) and Lyfgenia (Bluebird Bio) are approved for sickle cell disease, both using modified hematopoietic stem cells to boost fetal hemoglobin production. Backed by strong safety and efficacy data, their global regulatory filings and pediatric trials are ongoing, with adoption expected to rise sharply from 2025. Additionally, pipeline therapies from Beam Therapeutics and Editas Medicine are anticipated to enter the market later this decade, further driving segment growth.

List of Top Key Players:

Novartis AG, Vertex Pharmaceuticals Incorporated, bluebird bio, Inc., Emmaus Medical, Inc., Bristol-Myers Squibb Company., CHIESI FARMACEUTICI S.p.A., and Teva Pharmaceutical Industries Ltd.

Emerging Players

The emerging players in the sickle cell disease treatment market are Agios Pharmaceuticals, Inc., Beam Therapeutics, Editas Medicine, Novo Nordisk A/S, and Pfizer Inc., among others.

Key Industry Developments

December 2024 - Agios Pharmaceuticals, Inc. received a positive opinion from the European Commission (EC) for mitapivat as an orphan medicinal product (OMP) for sickle cell disease. Mitapivat, an oral small-molecule PK activator, achieved primary endpoints in Phase 3 ENERGIZE and ENERGIZE-T trials for transfusion-dependent alpha- or beta-thalassemia, prompting regulatory filings in the U.S., EU, KSA, and UAE.

December 2024 - Editas Medicine, Inc. shared updated RUBY trial data on Reni-cel for severe sickle cell disease, showing it was well tolerated with 27 of 28 patients free of vaso-occlusive events (VOEs) and early normalization of total hemoglobin.

Forecast Growth Projection:

Global Sickle Cell Disease Treatment Market Positioned for Strong Growth 2025-2032, Building on the steady momentum of 2024, the market is poised for remarkable expansion as leading players embrace innovative technologies and strategic advancements. This evolving landscape is unlocking lucrative opportunities for businesses to invest, scale, and stay ahead in an increasingly competitive and fast-moving market.

Market Research Process:

The Sickle Cell Disease Treatment Market research report by DataM Intelligence combines extensive Primary and Secondary research to provide powerful, in-depth insights. It examines key market drivers such as regulatory frameworks, evolving market conditions, competitive dynamics, historical trends, and breakthrough technologies, while spotlighting emerging innovations and potential challenges. This all-inclusive analysis uncovers high-growth opportunities and highlights possible barriers, equipping businesses to tackle market volatility and capture new avenues for success.

Buy Now & Get Instant Access to 360° Market Intelligence:- https://www.datamintelligence.com/buy-now-page?report=sickle-cell-disease-treatment-market

Market Segments:

The gene therapy segment is projected to record the fastest growth, with a CAGR of 17.5% during the forecast period.

Global Growth Regions:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Opens the report with a comprehensive market overview, highlighting key segments by region, product type, and application. It presents a clear snapshot of market size, growth potential by segment, and both short- and long-term outlook.

Chapter 2: Showcases the most impactful insights, uncovering the emerging trends and disruptive forces shaping the industry's future.

Chapter 3: Delivers an in-depth competitive landscape analysis of the Sickle Cell Disease Treatment market, covering revenue shares, strategic moves, and the latest mergers & acquisitions.

Chapter 4: Features detailed profiles of leading players, including their revenue streams, profit margins, product portfolios, and key milestones.

Chapters 5 & 6: Present a granular breakdown of regional and country-level revenue performance, offering a precise view of market size, opportunities, and development prospects worldwide.

Chapter 7: Analyzes market segmentation by product type, revealing the growth potential of each category and spotlighting high-impact.

Chapter 8: Examines application-based market growth, identifying the fastest-expanding sectors and lucrative opportunities for expansion.

Chapter 9: Maps the entire industry supply chain, providing insights into upstream and downstream activities for a complete market perspective.

Chapter 10: Concludes with key findings and actionable takeaways, guiding stakeholders toward strategic decisions and future growth opportunities.

Get Customization in the report as per your requirements:- https://datamintelligence.com/customize/sickle-cell-disease-treatment-market?kb

Q1: How Large is the Sickle Cell Disease Treatment Market?

A: The Sickle Cell Disease Treatment Market was valued at US$ 2.99 billion in 2024 and is expected to experience substantial growth, reaching US$ 9.97 billion by 2033.

Q2: How fast is the Sickle Cell Disease Treatment Market growing?

A: The Market is experiencing strong growth and is projected to expand at a CAGR of 14.8% from 2025 to 2032.

Q3: Which Region Leads Sickle Cell Disease Treatment Market growth?

A: North America SCD market grew from US$1.04B (2022) to US$1.14B (2023)

Try DataM Subscription Services free for 2 days - Get Started@ https://www.datamintelligence.com/reports-subscription?kb

Make smarter moves with real-time competitor insights, strategic forecasts, and global investment trends-get it all now!

Access your Subscription Dashboard today@ https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.